Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib

Phase 1

Completed

Conditions: Lung Adenocarcinoma

Interventions: Drug: erlotinib with cetuximab

First Posted Date: 2008-07-16

Last Posted Date: 2015-04-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT00716456

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memoral Sloan Kettering Cancer Center at Phelps, Sleepy Hollow, New York, United States

and more 2 locations

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

Phase 2

Active, not recruiting

Conditions: Mesothelioma

Interventions: Procedure: Pleurectomy/Decortication
Drug: pemetrexed and cisplatin or carboplatin
Radiation: Intensity Modulated Radiation Therapy

First Posted Date: 2008-07-15

Last Posted Date: 2024-05-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 65

Registration Number: NCT00715611

Locations: 🇺🇸
Memorial Sloan Kettering at Rockville Center, NY, Rockville Centre, New York, United States
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 9 locations

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 2

Terminated

Conditions: Bladder Cancer
URINARY BLADDER

Interventions: Drug: gemcitabine and cisplatin plus sorafenib

First Posted Date: 2008-07-14

Last Posted Date: 2015-11-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 2

Registration Number: NCT00714948

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Radiation: IMRT, cetuximab, docetaxel

First Posted Date: 2008-07-11

Last Posted Date: 2015-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT00713219

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Etoposide, carboplatin, ifosfamide
Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin
Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine

First Posted Date: 2008-07-10

Last Posted Date: 2022-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 96

Registration Number: NCT00712582

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

The Sexual Health of Rectal Cancer Patients

Completed

Conditions: Rectum
Rectal Cancer

Interventions: Behavioral: questionnaires
Behavioral: CSI-SH- Cancer Survivorship Intervention

First Posted Date: 2008-07-10

Last Posted Date: 2024-11-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 192

Registration Number: NCT00712751

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States

Physician-Patient Communication About Breast Cancer-Related Internet Information and Its Effect on Patient Satisfaction and Anxiety

Completed

Conditions: Breast Cancer

Interventions: Behavioral: questionnaires
Behavioral: audio recorded questionnaires
Behavioral: audio recordings , questionnaires

First Posted Date: 2008-07-10

Last Posted Date: 2015-02-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 85

Registration Number: NCT00712569

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center@Phelps, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors

Completed

Conditions: Uterine Cancer
Cervix Uteri Nos
Gestational Trophoblastic Disease

Interventions: Behavioral: questionnaire

First Posted Date: 2008-06-30

Last Posted Date: 2018-04-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 59

Registration Number: NCT00706875

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma

Phase 2

Completed

Conditions: Hodgkin's Disease
Lymphoma

Interventions: Drug: bendamustine hcl

First Posted Date: 2008-06-26

Last Posted Date: 2017-03-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 36

Registration Number: NCT00705250

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the Immunological Adjuvant Alhydrogel

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Biological: rsPSMA protein plus Alhydrogel® vaccine

First Posted Date: 2008-06-26

Last Posted Date: 2012-01-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 14

Registration Number: NCT00705835

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy